What is ANI Pharmaceuticals's market cap?

ANI Pharmaceuticals (ANIP) has a market capitalization of $1.8B and trades on NASDAQ.

What is ANI Pharmaceuticals's revenue and profitability?

ANI Pharmaceuticals generated $923.7M in trailing twelve-month revenue with net income of $92.1M, representing a net margin of 10.0%. Gross margin stands at 60.8%, with free cash flow of $191.2M. These figures are based on the Q1 2026 filing.

Who are ANI Pharmaceuticals's competitors?

ANI Pharmaceuticals's key competitors include Amneal Pharmaceuticals, Inc., Viatris Inc., Alnylam Pharmaceuticals, Inc., and others. These companies compete in similar markets and product categories.

Who does ANI Pharmaceuticals partner with?

ANI Pharmaceuticals's notable partners include JPMorgan Chase Bank, N.A., Truist Bank.

What subsidiaries does ANI Pharmaceuticals have?

ANI Pharmaceuticals's subsidiaries include Alimera Sciences, Inc..

Where is ANI Pharmaceuticals headquartered?

ANI Pharmaceuticals is headquartered in United States of America and employs approximately 642 people. It has been publicly traded since 1999.

ANI Pharmaceuticals

ANIP

ANI Pharmaceuticals is a diversified biopharmaceutical company focused on developing, manufacturing, and commercializing therapeutics for rare diseases, brands, and generic markets.

Market cap

$1.78B+28.5%

Revenue$923.7M+37.0%

Net income$92.1M+538%

Free cash flow$191.2M+187%

EPS (diluted)$3.94+410%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 8, 2026

Revenue$237.5MBeat by $29.8M EPS$2.05Beat by $0.77

Read the full report

Next report

Aug 7, 2026 (In 1 week)

Revenue estimate$260.1M

EPS estimate$2.01

Financials

Q1 2026

Income statement

See full

Revenue$237.5M+20.5%

Gross profit$143.9M+16.0%

Operating income$38.9M+48.5%

Net income$29.5M+88.1%

EPS (diluted)$1.28+85.5%

Balance sheet

See full

Cash & equivalents$311.2M+108%

Total debt$305.3M-3.5%

Total equity$562.3M+34.3%

Total assets$1.4B+10.0%

Cash flow

See full

Operating cash flow$58.4M+66.8%

CapEx$6.1M+146%

Free cash flow$52.3M+60.8%

Valuation & ratios

Valuation

See full

Market cap$1.78B+28.5%

Enterprise value$1.78B+15.6%

P/E19.3×—

P/S1.9×0.0×

Profitability

See full

Gross margin60.8%+1.5pp

Operating margin13.4%—

Net margin10%+8.1pp

FCF margin20.7%+10.8pp

Returns & leverage

See full

Return on equity18.8%+15.6pp

Debt / equity0.5×-0.2×

Current ratio3.1×+0.5×

Competitors

By market cap

ALN

Alnylam Pharmaceuticals$37.2B-12.2%

Viatris$20.5B+89.0%

Amneal Pharmaceuticals, Inc.$5.8B+126%

ANI Pharmaceuticals$1.8B+23.7%

AnaptysBio, Inc.$1.6B+103%

Eton Pharmaceuticals, Inc.$1.2B+188%

Zevra Therapeutics, Inc.$574.0M-2.9%

Fulcrum Therapeutics, Inc.$248.5M-41.0%

By revenue growth

Zevra Therapeutics, Inc.+201%

AnaptysBio, Inc.+108%

ALN

Alnylam Pharmaceuticals+82.6%

Eton Pharmaceuticals, Inc.+79.9%

ANI Pharmaceuticals+37.0%

Amneal Pharmaceuticals, Inc.+7.6%

Viatris+1.6%

By net margin

Zevra Therapeutics, Inc.101.58%+328pp

ALN

Alnylam Pharmaceuticals11.72%+21.5pp

ANI Pharmaceuticals9.98%+13.1pp

Amneal Pharmaceuticals, Inc.4.01%+4.5pp

Viatris-2.04%+24.4pp

Eton Pharmaceuticals, Inc.-9.5%+2.7pp

AnaptysBio, Inc.-49.94%+80.0pp

Profile

ANI Pharmaceuticals is a diversified biopharmaceutical company focused on developing, manufacturing, and commercializing therapeutics for rare diseases, brands, and generic markets. The company leverages its internal R&D and strategic acquisitions to deliver high-quality medicines to patients with unmet medical needs. Its value proposition is built on a robust manufacturing infrastructure and a growing portfolio of specialized pharmaceutical products.

Competitive position

ANI Pharmaceuticals maintains a competitive edge through its specialized manufacturing facilities and a diversified portfolio that balances high-growth rare disease assets with a stable, high-volume generics business.

GeographiesUnited States, Europe, Canada

Customer segmentsHealthcare Providers, Pharmaceutical Wholesalers, Specialty Pharmacies

Business modelManufacturing, Research and Development, B2B Sales

SuppliersActive Pharmaceutical Ingredient (API) suppliers, Raw material providers, Contract research organizations

CustomersDrug wholesalers, Retail pharmacy chains, Specialty distributors, Hospitals and clinics

CountryUnited States of America

Listed1999

Employees642.0

CEONikhil Lalwani

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Websiteanipharmaceuticals.com

FilingsSEC EDGAR

Ask your AI about ANI Pharmaceuticals.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ANI Pharmaceuticals's market cap?: ANI Pharmaceuticals (ANIP) has a market capitalization of $1.8B and trades on NASDAQ.
What is ANI Pharmaceuticals's revenue and profitability?: ANI Pharmaceuticals generated $923.7M in trailing twelve-month revenue with net income of $92.1M, representing a net margin of 10.0%. Gross margin stands at 60.8%, with free cash flow of $191.2M. These figures are based on the Q1 2026 filing.
Who are ANI Pharmaceuticals's competitors?: ANI Pharmaceuticals's key competitors include Amneal Pharmaceuticals, Inc., Viatris Inc., Alnylam Pharmaceuticals, Inc., and others. These companies compete in similar markets and product categories.
Who does ANI Pharmaceuticals partner with?: ANI Pharmaceuticals's notable partners include JPMorgan Chase Bank, N.A., Truist Bank.
What subsidiaries does ANI Pharmaceuticals have?: ANI Pharmaceuticals's subsidiaries include Alimera Sciences, Inc..
Where is ANI Pharmaceuticals headquartered?: ANI Pharmaceuticals is headquartered in United States of America and employs approximately 642 people. It has been publicly traded since 1999.